Patents by Inventor Jeffrey Kroll Adams

Jeffrey Kroll Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxycholesterol immunoassay
    Patent number: 8969525
    Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: March 3, 2015
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS
    Publication number: 20130245321
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: October 11, 2012
    Publication date: September 19, 2013
    Inventors: SARAH SPIEGEL, ROBERT ELLIOT ZIPKIN, JEFFREY KROLL ADAMS
  • Sphingosine kinase type 1 inhibitors, compositions and processes for using same
    Patent number: 8372888
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 12, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors, and processes for using same
    Patent number: 8314151
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: November 20, 2012
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME
    Publication number: 20120237448
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: August 31, 2009
    Publication date: September 20, 2012
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • HYDROXYCHOLESTEROL IMMUNOASSAY
    Publication number: 20120115169
    Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.
    Type: Application
    Filed: November 9, 2010
    Publication date: May 10, 2012
    Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.
    Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
  • Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same
    Publication number: 20100278741
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: August 31, 2009
    Publication date: November 4, 2010
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same
    Publication number: 20100035959
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Application
    Filed: April 29, 2009
    Publication date: February 11, 2010
    Applicant: ENZO THERAPEUTICS, INC.C/O ENZO BIOCHEM, INC.
    Inventors: Robert Elliot Zipkin, Sarah Spiegel, Jeffrey Kroll Adams